| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| host | mouse |
| isotype | IgG2a |
| clonality | monoclonal |
| concentration | 1 mg/mL |
| applications | ICC/IF, WB |
| reactivity | Progesterone Receptor |
| available sizes | 100 µg |
mouse anti-Progesterone Receptor monoclonal antibody (4D8) 5585
$503.00
Antibody summary
- Mouse monoclonal to Progesterone Receptor
- Suitable for: WB
- Isotype: IgG2a
- 100 µg
mouse anti-Progesterone Receptor monoclonal antibody (4D8) 5585
| antibody |
|---|
| Tested applications WB |
| Recommended dilutions Immunoblotting: use at 1-5 ug/ml. Positive controls: MCF7 cells or recombinant protein. |
| Immunogen 6-His fusion protein containing the region encoding aa 1-101 of human progesterone receptor expressed in E. coli. |
| Size and concentration 100µg and lot specific |
| Form liquid |
| Storage Instructions This antibody is stable for at least one (1) year at -70°C. Avoid multiple freeze-thaw cycles. |
| Storage buffer PBS, pH 7.4 |
| Purity protein affinty purification |
| Clonality monoclonal |
| Isotype IgG2a |
| Compatible secondaries goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody 5486 goat anti-mouse IgG, H&L chain specific, biotin conjugated, Conjugate polyclonal antibody 2685 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody 7854 goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody, crossabsorbed 1706 goat anti-mouse IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1716 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1721 |
| Isotype control Mouse monocolonal IgG2a - Isotype Control |
| target relevance |
|---|
| Protein names Progesterone receptor (PR) (Nuclear receptor subfamily 3 group C member 3) |
| Gene names PGR,PGR NR3C3 |
| Protein family Nuclear hormone receptor family, NR3 subfamily |
| Mass 98981Da |
| Function FUNCTION: The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as a transcriptional activator or repressor. {ECO:0000269|PubMed:10757795, ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067, ECO:0000305}.; FUNCTION: [Isoform A]: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2. {ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103, ECO:0000269|PubMed:8264658, ECO:0000305, ECO:0000305|PubMed:10757795}.; FUNCTION: [Isoform B]: Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation. {ECO:0000269|PubMed:7969170}.; FUNCTION: [Isoform 4]: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone. |
| Subellular location SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmic shuttling is both hormone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases.; SUBCELLULAR LOCATION: [Isoform A]: Nucleus. Cytoplasm. Note=Mainly nuclear.; SUBCELLULAR LOCATION: [Isoform 4]: Mitochondrion outer membrane {ECO:0000269|PubMed:23518922}. |
| Tissues TISSUE SPECIFICITY: In reproductive tissues the expression of isoform A and isoform B varies as a consequence of developmental and hormonal status. Isoform A and isoform B are expressed in comparable levels in uterine glandular epithelium during the proliferative phase of the menstrual cycle. Expression of isoform B but not of isoform A persists in the glands during mid-secretory phase. In the stroma, isoform A is the predominant form throughout the cycle. Heterogeneous isoform expression between the glands of the endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli. {ECO:0000269|PubMed:11041221}. |
| Structure SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2; the interaction promotes ubiquitination, decreases sumoylation, and represses transcriptional activity. Interacts with PIAS3; the interaction promotes sumoylation of PR in a hormone-dependent manner, inhibits DNA-binding, and alters nuclear export. Interacts with SP1; the interaction requires ligand-induced phosphorylation on Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform A interacts with NCOR2. Isoform B (but not isoform A) interacts with NCOA2 and NCOA1. Isoform B (but not isoform A) interacts with KLF9. Interacts with GTF2B (PubMed:1517211). {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795, ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:1517211, ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}. |
| Post-translational modification PTM: Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1. {ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801, ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977, ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.; PTM: Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294. {ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.; PTM: Ubiquitination is hormone-dependent and represses sumoylation on the same site. Promoted by MAPK-mediated phosphorylation on Ser-294. {ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.; PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation. {ECO:0000269|PubMed:22031296}. |
| Target Relevance information above includes information from UniProt accession : P06401 |
| The UniProt Consortium |
Data
| No results found |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.| pmid | title | authors | citation |
|---|
Protocols
| relevant to this product |
|---|
| Western blot IHC ICC |
Documents
| # | |||
|---|---|---|---|
| No results found | |||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.